Keravision to raise $48 million in offering:
This article was originally published in Clinica
Executive Summary
Keravision, which has developed the Intacs corneal ring implant to treat vision disorders, plans to raise around $48 million net from an offering of four million shares at $13 each. The Fremont, California-based company will use the proceeds for the launch and marketing of Intacs in the US, where it has been cleared by the FDA for the treatment of mild myopia. The company also intends to continue development and clinical testing of further products based on its technology.